CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine

Discovering that calcitonin-related peptide (CGRP) plays a key role in the complex pathophysiology of migraine has allowed us to make great strides in the development of new approaches for acute and preventive treatment. This evidence has led to the development of small molecules antagonist molecule...

Descripción completa

Detalles Bibliográficos
Autores principales: Capi, Matilde, De Angelis, Valerio, De Bernardini, Donatella, De Luca, Ottavia, Cipolla, Fabiola, Lionetto, Luana, Simmaco, Maurizio, Martelletti, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038117/
https://www.ncbi.nlm.nih.gov/pubmed/33916043
http://dx.doi.org/10.3390/jcm10071429
Descripción
Sumario:Discovering that calcitonin-related peptide (CGRP) plays a key role in the complex pathophysiology of migraine has allowed us to make great strides in the development of new approaches for acute and preventive treatment. This evidence has led to the development of small molecules antagonist molecules of the CGRP receptor (“gepants”) and of a new class of medications called “Ditans”. This review presents the data from clinical trials reporting the efficacy, safety, and tolerability of the new drugs used in the treatment of migraines. Evidences show that therapeutic approaches targeted to CGRP have the potential to transform the clinical management of migraine, even though its appropriate place has yet to be determined with accuracy.

Ejemplares similares